Kein Folientitel

1
ERA-NET PathoGenoMics 2nd NSC 3rd EB Meeting,
April 07, 2005 Strategic supporting measures to
raise synergies with the European framework
programmes and to embed PathoGenoMics into the
European RD Landscape
National Contact Point LIFESCIHEALTH Dr.
Wilfried Diekmann Königswinterer Str. 522-524,
53227 Bonn phone [phone], e-mail
wilfried.diekmann_at_dlr.de http//www.nks-lebenswiss
enschaften.de
2
TP 1 Life Science, Genomics and Biotechnology for
Health Programme structure and pathogenomics-relev
ant areas
i) Advanced Genomics and its applications for
health
a) Fundamental knowledge basic tools for
functional genomics in all organisms
Comparative genomics and population genetics
Multidisciplinary functional genomics approaches
to basic biological processes
Gene expression and proteomics
Bio-informatics
Structural genomics
Innovative research in post-genomics with high
potential for application
New in vitro tests to replace animal experimentati
on
New preventive and therapeutic tools (somatic
gene and cell therapies stem cell and
immunotherapies, etc.)
New, safer,more effective drugs (incl.
pharmaco-genomics)
New diagnostics
ii) Combating major diseases
c) Poverty- related diseases
b) Cancer

• HIV / AIDS
• Malaria
• Tuberculosis

3
3rd Call (FP-2004-LIFESCIHEALTH-5, deadline
16.11.2004) Selected pathogenomics-relevant areas
4
FP6 project portfolio in pathogenomics Pathogenomi
cs-relevant proposals to the 3rd Call

10
2
based on panel priority lists, i.e. major
priority lists of COM services are not yet
available
5
FP6 project portfolio in pathogenomics TP LSH,
Fundamental Genomics, Outcome 3rd Call

• STREP
• Non-coding RNAs in bacterial pathogenicity
  (BACRNAs)
• Major Priority List Coordinator University of
  Vienna, AT
• CA
• Strategy to build up and maintain an integrated
  sustainable European fungal genomic database
  required for innovative genomics research on
  filamentous fungi important for biotechnology and
  human health (EUROFUNGBASE)
• Major Priority List Coordinator Universiteit
  Leiden, NL

6
FP6 project portfolio in pathogenomics TP LSH,
Major Diseases, Outcome 3rd Call

• NoE
• Genomics to Combat Resistance against Antibiotics
  in Community-acquired Lower Respiratory Tract
  Infections in Europe (GRACE)
• NI Panel Priority Order 10 Coordinator
  Universiteit Antwerpen BE
• STREPs
• Combating resistance to antibiotics (CORANIX)
• TI Panel Priority Order 7 Coordinator Institut
  Pasteur, FR
• Effects of antibiotic resistance on bacterial
  fitness, virulence and transmission
• (EAR)
• TI Panel Priority Order 9 Coordinator Uppsala
  University, SE
• Role of Mobile Genetic Elements in the Spread of
  Antimicrobial Drug
• Resistance (DRESP2)
• TI Panel Priority Order 10 Coordinator
  Universita degli Studi di Siena, IT
• Functional genomic characterisation of molecular
  determinants for
• staphylococcal fitness, virulence and drug
  resistance (StaphDynamics)
• TI Panel Priority Order 16 Coordinator
  University of Groningen, NL

7
FP6 project portfolio in pathogenomics TP LSH,
Major Diseases, Outcome 3rd Call

• Further STREPs passed the threshold
• Antifungal drug resistance in the human pathogen
  Candida glabrata (ANTIGLA)
• TI Panel Priority Order 18 Coordinator
  Instituto Superior Técnico, PT
• Combating Candida drug resistance, CDR, by novel
  drugs especially acting
• through interference with CDR regulatory network
  (CombatingCDR)
• TI Panel Priority Order 19 Coordinator
  Universität Bonn, DE
• Factors affecting transfer and mobilization of
  extended spectrum beta-
• lactamases (MOBILACT)
• TI Panel Priority Order 21 Coordinator
  University of Warwick, UK
• ADaptation of VANComycin-resistant Enterococci
  and Staphylococci
• Ecological determinants of fitness and virulence
• (ADVANCES)
• TI Panel Priority Order 22 Coordinator
  University Medical Centre Utrecht, NL

8
FP6 project portfolio in pathogenomics TP LSH,
Major Diseases (Cancer), Outcome 3rd Call

• IPs
• The role of chronic INfections in the development
  of CAncer (INCA)
• NI Panel Priority Order 3 Coordinator
  Medizinische Hochschule Hannover, DE
• Linking Cancer Transcriptome to Proteome
  Functional Oncogenomics for
• Diagnosis and Treatment of Human Cancers related
  to Infectious Agents
• (EUROVIRC)
• NI Panel Priority Order 12 Coordinator
  Fondazione Andrea Cesalpino, IT

9
FP6 project portfolio in pathogenomics TP LSH,
Poverty-related diseases (i.e. tuberculosis),
Outcome 3rd Call

• IPs
• New medicines for tuberculosis (NM4TB)
• NI Panel Priority Order 1 Coordinator Institut
  Pasteur, FR
• A Consortium for Tuberculosis Drug Development
  (TB-DD)
• NI Panel Priority Order 7 Coordinator
  University of Zürich, CH
• STREPs
• Innate and adaptive immunity in clinical and
  experimental mycobacterial infection in neonates
  and infants (NEOTIM)
• TI Panel Priority Order 5 Coordinator
  Karolinska Institutet, SE
• New drugs for persistent tuberculosis
  Exploitation of 3-D structure of novel targets,
  lead optimisation and functional in vivo
  evaluation (NewTBDrugs)
• TI Panel Priority Order 6 Coord. LIONEX
  Diagnostics Therapeutics GmbH, DE

10
Framework Programme 6, LIFESCIHEALTH Fundamental
Genomics, Topics for 4th Call

• Gene expression and proteomics
• A systems approach to understanding the
  regulation of gene transcription IP
• Structural genomics
• Structural genomics interdisciplinary initiative
  IP
• Comparative genomics and population genetics
• Functional genomics in Arabidopsis thaliana - IP
  
• High throughput phenotyping tools and approaches
  for large scale functional
• genomics studies IP
• Population cohorts for molecular epidemiological
  studies in European populations IP
• Multidisciplinary functional genomics approaches
  to basic biological processes
• Functional genomics of autosomal aneuploid
  syndromes - IP
• The biological role of small regulatory RNAs -
  IP
• Specific Support Actions (SSAs)

11
Framework Programme 6, LIFESCIHEALTH Biotech
Applied Genomics, Topics for 4th Call

• New, safer, more effective drugs including
  pharmacogenomics
• Marker profiling as a new tool for predictive
  toxicology - IP
• New tools to investigate ADME properties of
  drugs involving a carrier system STREP
• New diagnostics
• High throughput molecular diagnostics for
  hereditary diseases - IP
• Development of innovative methods for diagnosis
  of nervous system disorders STREP
• Nanoparticles-based diagnostics STREP
• New in vitro tests to replace animal
  experimentation
• Predictive in vitro testing strategies for human
  exposure to chemicals - IP
• Workshop on business opportunities for in vitro
  pharmaceutical toxicology SSA
• Researchers and regulators meet manufacturers of
  toxicology test methods SSA
• New preventive therapeutic tools, somatic gene
  and cell therapies, stem cells, immunotherapies
• Tissue engineering approaches to treating
  children with birth defects - IP
• Hepatitis C vaccine - IP
• Stem Cell Therapy for Stroke Patients STREP
• Methodological research to underpin stem cell
  banking - STREP

12
Framework Programme 6, LIFESCIHEALTH Major
Diseases, Topics for 4th Call

• A) APPLICATIONS-ORIENTATED GENOMIC APPROACHES
• General (overarching)
• Genetic control of the pathogenesis of diseases
  based on iron metabolism STREP
• Combating, cardiovascular disease, diabetes and
  rare diseases
• Genomic-wide mapping and functional genomics of
  susceptibility to coronary artery disease IP
• Hypertension and cardiovascular disease NOE
• Prevention of accelerated cardiovascular death
  in uraemia and end-stage renal disease - STREP
• Functional genomics and regulatory networks in
  lipid metabolism their effects on atherogenic
• vascular disease development - STREP
• Gene-environment interaction on the incidence of
  type 2 diabetes - IP
• Molecular pathways underlying decreased beta
  cell mass in diabetes mellitus STREP
• Rare inherited neuromuscular disorders from
  molecular basis to cutting edge therapies - NOE
• Rare disorders of protein folding STREP
• Rare diseases of connective tissues affecting
  bone and/or cartilage STREP
• Research on cardiovascular and/or
  cerebrovascular disease STREP towards SME
• Preventive and therapeutic strategies for Type 1
  diabetes STREP towards SME
• Development of in vitro and/or animal models for
  rare diseases STREP towards SME

13
Framework Programme 6, LIFESCIHEALTH Major
Diseases, Topics for 4th Call

• Combating resistance to antibiotics and other
  drugs
• Control of antimicrobial resistance in hospital
  acquired and health care associated infections
  IP
• Molecular ecology of antibiotic drug resistance
  IP
• Workshop exploring novel opportunities towards
  vaccines and control of anti-bacterial resistance
  - SSA
• New diagnostic tests for the management
  control of antimicrobial resistance STREP
  towards SME
• Novel principles for anti-microbial treatment
  STREP towards SME
• Studying the brain and combating diseases of the
  nervous system
• Functional genomics and neurobiology of epilepsy
  IP
• Neuroimaging Bridging genetics and neural
  function IP
• Cortical information processing STREP
• Schizophrenia from genotype to phenotype
  STREP
• Initiative in neuroinformatics SSA
• Neuroscience-oriented new technologies STREP
  towards SME
• Animal models for neurological and psychiatric
  diseases STREP towards SME
• Early markers and new targets for
  neurodegenerative diseases STREP towards SME
• Perinatal brain damage early markers and
  neuroprotection STREP towards SME
• Studying human development and the ageing process

14
Framework Programme 6, LIFESCIHEALTH Major
Diseases (Cancer), Topics for 4th Call

• COMBATING CANCER
• Modulation of apoptosis in cancer prevention and
  therapy IP
• Broadening the knowledge base on the molecular
  mechanisms underlying chemotherapy
• resistance, therapeutic escape, efficacy and
  toxicity IP
• Early diagnosis and novel therapies of solid
  childhood cancers STREP
• Innovative research on palliative care in
  patients with advanced stages of cancer STREP
• Role of chromosomal aberrations and epigenetic
  mechanisms of leukaemia STREP
• Identification and validation of biomarkers in
  molecular cancer epidemiology STREP
• Exploring the patients cancer stem cell as a
  novel therapeutic target STREP
• Conference on cell differentiation, plasticity
  and cancer SSA
• Innovative technological approaches for cancer
  therapy STREP towards SMEs
• Small-ligand libraries improved tools for
  exploration and prospective anti-tumor therapy
• - STREP towards SMEs
• Improving resolution of current imaging devices
  relevant to cancer diagnosis and therapy
• - STREP towards SMEs
• Application of molecular signatures for the
  early diagnosis of cancer patients
• - STREP towards SMEs

15
Framework Programme 6, LIFESCIHEALTH Poverty-relat
ed diseases (PRD), Topics for 4th Call

• CONFRONTING THE MAJOR COMMUNICABLE DISEASES
  LINKED TO POVERTY
• HIV/AIDS Therapeutic Clinical trials network -
  NOE
• HIV/AIDS Vaccines/Microbicides Network - NOE
• Rationale Design of Malaria Vaccine - IP
• New approaches for research into
  host/vector-pathogen interaction for HIV/AIDS,
  malaria and tuberculosis STREP
• Undesirable consequences of drugs and vaccines
  for Poverty-related Diseases STREP
• Integration coordination of European clinical
  research on PRD - SSA/CA
• Promotion of PRD research - SSA/CA
• European Network for vaccine development
  covering the three diseases - SSA/CA
• Improving participation of the private sector in
  PRD research SSA towards SME
• SME-driven innovations for poverty related
  diseases STREP towards SME
• Development of fast tests for diagnosis of
  poverty related diseases suitable for use in
  resource-poor settings STREP towards SME
• Innovative delivery mechanism for treatment and
  depot therapy in Poverty-related diseases
  STREP towards SME

16
Framework Programme 6, LIFESCIHEALTH Specific
Support Actions across TP1 Topics for 4th Call

• Promoting Collaboration between SMEs and
  Academia
• Stimulating international co-operation
• Promotion of cooperation with Associated
  Candidate Countries (ACC)
• Realising ERA objectives
• Life sciences and biotechnology A strategy for
  Europe.
• Supporting policy development
• Scientific and project management
• Mapping and identifying research efforts and
  contributions from FPs in the context of the
  European Communitys Public Health Programme, in
  the fields of health information, health threats
  and health determinants, with particular regard
  to mental health, reducing health risks, and
  preventing major as well as specific diseases.
• Mapping and identifying research efforts and
  contributions from FPs in the context of the
  European Environment and Health Action Plan, in
  the fields of gene-environment interactions,
  respiratory diseases, neuro-developmental
  disorders, cardiovascular diseases and cancers,
  with particular regard to childrens health
• Foresight study in the area of biotechnology and
  health
• European human embryonic stem cell registry